STT3B: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It’s the GeneMedi’s summary page for Target/Biomarker Introduction of STT3B. The page also collects GeneMedi’s different modalities and formats products for STT3B in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi’s target-insight database-GM ITD database, the STT3B target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Introcelluar Protein.
The protein encoded by this gene is a catalytic subunit of a protein complex that transfers oligosaccharides onto asparagine residues. Defects in this gene are a cause of congenital disorder of glycosylation Ix (CDG1X). [provided by RefSeq, Jun 2014]
|
Target ID |
GM-IP1846
|
|
Target Name |
STT3B
|
|
Gene ID |
201595
|
|
Gene Official Name |
STT3B
|
|
Gene Alias |
CDG1X, SIMP, STT3-B
|
|
Protein Sub-location |
Introcelluar Protein
|
|
Category |
|
Pre-made anti-STT3B monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research.
Pre-made anti-STT3B monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-STT3B mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Warning: Undefined array key "category" in /www/wwwroot/genemedi_com0630/wp-content/plugins/wc-product-table-pro/pro/functions.php on line 2278
